Related Experiment Videos
NCCN and ELN: What do the guidelines tell us?
Kendra Sweet1, Javier Pinilla-Ibarz1
1Moffitt Cancer Center, Tampa, FL, United States.
Abstract:
The prognosis for patients with Chronic Myeloid Leukemia is vastly different in 2016 compared to 20 years ago, and this is due to the development of BCR-ABL tyrosine kinase inhibitors (TKIs). As newer, more potent, TKIs have been developed and approved over the past 15 years, the decision about which drug to use as first line therapy, and when to switch treatment in particular patients has become more complicated. The National Comprehensive Cancer Network (NCCN) and the European LeukemiaNet (ELN) have developed treatment and monitoring guidelines to aide in the management of these patients. The guidelines were developed by two groups of CML experts and recommendations are based on available data and expert opinion. With adherence to the recommendations proposed by the NCCN and ELN, we can expect to continue to see excellent outcomes for our patients with CML.
Insights
The development of BCR-ABL tyrosine kinase inhibitors (TKIs) has transformed Chronic Myeloid Leukemia (CML) treatment. Adhering to National Comprehensive Cancer Network (NCCN) and European LeukemiaNet (ELN) guidelines ensures excellent patient outcomes.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chronic Myeloid Leukemia (CML) prognosis has dramatically improved over the last two decades.
- This improvement is attributed to the advent and evolution of BCR-ABL tyrosine kinase inhibitors (TKIs).
- The increasing number and potency of TKIs present complex treatment decisions for clinicians.
Purpose of the Study:
- To review the impact of BCR-ABL tyrosine kinase inhibitors (TKIs) on Chronic Myeloid Leukemia (CML) prognosis.
- To highlight the role of National Comprehensive Cancer Network (NCCN) and European LeukemiaNet (ELN) guidelines in managing CML.
- To emphasize the importance of expert-driven recommendations for optimizing CML patient care.
Main Methods:
- Review of current literature and treatment guidelines for Chronic Myeloid Leukemia (CML).
- Analysis of the impact of various BCR-ABL tyrosine kinase inhibitors (TKIs) on patient outcomes.
- Synthesis of recommendations from expert panels, including the National Comprehensive Cancer Network (NCCN) and European LeukemiaNet (ELN).
Main Results:
- BCR-ABL tyrosine kinase inhibitors (TKIs) have significantly improved survival rates for Chronic Myeloid Leukemia (CML) patients.
- Treatment selection and timing have become more complex due to the availability of multiple TKIs.
- Established guidelines from NCCN and ELN provide a framework for effective CML management.
Conclusions:
- Adherence to NCCN and ELN guidelines is crucial for achieving excellent outcomes in Chronic Myeloid Leukemia (CML) patients.
- Continued research and expert consensus are vital for refining CML treatment strategies.
- The evolution of TKIs offers a promising future for individuals diagnosed with CML.